News | April 30, 2009

Ohio State University, Cardinal Health, State of Ohio to Invest $10 Million To Advance Medical Imaging

April 30, 2009 - The Ohio State University, Cardinal Health and Ohio Third Frontier announced a collaboration that will invest more than $10 million to help shape the future of the medical diagnostic industry, combining Ohio State's Wright Center of Innovation in Biomedical Imaging research capabilities and Cardinal Health's manufacturing and commercialization expertise for molecular imaging agents.

Molecular imaging is one of the fastest growing areas in biotechnology, where specialized pharmaceuticals are injected into the body and seek out cellular functions related to specific disease. These imaging agents are visible using sophisticated imaging equipment, resulting in the ability to diagnose disease before a patient exhibits symptoms.

The partnership will expand OSU's Wright Center of Innovation in Biomedical Imaging to include a new Molecular Imaging Technology Center. The center will house Ohio State's researchers, as well as Cardinal Health's radiopharmaceutical manufacturing facility and nuclear pharmacy operations. Also, a distinguished faculty position in radiopharmaceutical chemistry will be added to Ohio State's department of radiology.

The new Molecular Imaging Technology Center will provide Ohio State researchers with unique manufacturing capabilities and expertise to aid development of new molecular imaging agents in positron emission tomography (PET imaging). Cardinal Health will support manufacturing and dispensing of these agents for clinical trials across its national network of radiopharmaceutical facilities.

"While we expect to immediately create up to a dozen highly-skilled jobs with this exciting new partnership, the true value is collaborating with Ohio State and Cardinal Health to attract the best and brightest researchers to Ohio and continue to diversify our state's economy," said Lt. Gov. Lee Fisher.

"Never before has the University's role in generating long-term economic growth been more evident," said E. Gordon Gee, president of the university. "The Wright Center of Innovation in Biomedical Imaging is an excellent example, creating some 280 jobs, attracting or launching nine companies and generating a 10-to-1 return on the state's investment."

John Rademacher, president of Cardinal Health's Nuclear Pharmacy business said, "Researchers and industry alike will be attracted to the Molecular Imaging Technology Center as a one-stop shop for research, development, clinical investigational trials and full commercialization of new molecular imaging agents."

For more information:

Related Content

Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior

Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior. Image courtesy of Christian Lohrmann, Jason Lewis, Wolfgang Weber, Memorial Sloan Kettering Cancer Center; MabVax Therapeutics

News | PET-CT | June 14, 2017
Pancreatic cancer is associated with bleak five-year survival rates and limited treatment options, but new research is...

While subject No. 1 (left) was judged as positive for both the neuronal injury and the amyloid load biomarker, both Alzheimer's disease biomarkers were negative in subject No. 2 (right). Image courtesy of Henryk Barthel et al., University Hospital Leipzig, Leipzig, Germany

News | PET Imaging | June 14, 2017
More people die of Alzheimer's disease than prostate and breast cancer combined. Identifying the disease before major...
Bennett S. Greenspan, M.D.

Bennett S. Greenspan, M.D.

News | Molecular Imaging | June 13, 2017
Bennett S. Greenspan, M.D., MS, FACNM, FACR, professor of radiology at the Medical College of Georgia, Augusta...
PET/CT
News | PET-CT | June 12, 2017
Philips announced that it will be showcasing molecular imaging solutions highlighting Philips’ commitment to innovation...
News | PET-CT | June 12, 2017
Siemens Healthineers has announced that the Food and Drug Administration (FDA) has cleared Biograph Horizon Flow...
advanced visualization
News | Molecular Imaging | June 09, 2017
The Food and Drug Administration (FDA) has cleared syngo.via VB20 for Molecular Imaging (MI) from Siemens Healthineers...
Gamma Medica, LumaGEM molecular breast imaging system, MBI, Mercy Medical Center, Long Island, first New York install
News | Breast Imaging | April 04, 2017
Gamma Medica announced in late March that Mercy Medical Center, a member of Catholic Health Services of Long Island,...
Gamma Medica, European breast imaging market, LumaGem MBI, molecular breast imaging, Hospital Services Limited
News | Molecular Imaging | March 02, 2017
Gamma Medica announced it has partnered with Hospital Services Limited (HSL), a Dublin, Ireland-based established ...
Overlay Init